Apellis Pharmaceuticals Inc (APLS) — Cash Flow-to-Debt Ratio
Apellis Pharmaceuticals Inc (APLS) has a Cash Flow-to-Debt Ratio of -0.09x as of March 2026, meaning its operating cash flow of $-60.97 Million could theoretically repay 0% of its total liabilities ($667.61 Million) in one year. See Apellis Pharmaceuticals Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apellis Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Apellis Pharmaceuticals Inc across 13 annual periods. For the full cash flow conversion analysis, see Apellis Pharmaceuticals Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Apellis Pharmaceuticals Inc (2013–2025)
Year-by-year debt coverage analysis for Apellis Pharmaceuticals Inc. Check Apellis Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | $45.33 Million | $705.11 Million | ▲ +148.0% |
| 2024 | -0.13x | $-87.87 Million | $656.51 Million | ▲ +86.6% |
| 2023 | -1.00x | $-594.74 Million | $594.21 Million | ▼ -15.0% |
| 2022 | -0.87x | $-513.75 Million | $590.35 Million | ▼ -5.6% |
| 2021 | -0.82x | $-563.13 Million | $683.10 Million | ▼ -288.3% |
| 2020 | -0.21x | $-160.49 Million | $756.01 Million | ▲ +64.3% |
| 2019 | -0.59x | $-211.13 Million | $355.02 Million | ▲ +80.7% |
| 2018 | -3.08x | $-131.24 Million | $42.56 Million | ▼ -119.6% |
| 2017 | -1.40x | $-46.60 Million | $33.19 Million | ▲ +80.4% |
| 2016 | -7.15x | $-26.00 Million | $3.64 Million | ▼ -21.3% |
| 2015 | -5.89x | $-18.86 Million | $3.20 Million | ▲ +35.9% |
| 2014 | -9.20x | $-9.95 Million | $1.08 Million | ▼ -80.7% |
| 2013 | -5.09x | $-3.44 Million | $676.96K | — |